BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best high growth European stocks to buy. On January 7, Citizens reaffirmed its Market Outperform rating and $396 price target for BeOne Medicines Ltd. (NASDAQ:ONC), citing strong effectiveness results from a Phase 3 trial in gastric cancer patients. BeOne Medicines Ltd. and Jazz Pharmaceutics shared further findings from the HERIZON-GEA-01 trial, which revealed high efficacy in patients with advanced gastric or gastroesophageal adenocarcinoma (GEA).
Citizens observed that BeOne’s Brukinsa was on track to generate about $3.8 billion in revenue in 2025, thanks to an impressive development pipeline that includes numerous assets across diverse indications.
The company also revealed the first clearance for sonrotoclax, its next-generation BCL2 inhibitor, which Citizens anticipates could contribute to subsequent approvals worldwide.
At the same time, the firm emphasized BeOne’s $4.1 billion cash position and stated that the recent share price decline represented a “unique buying opportunity” in one of the world’s leading hematology/oncology companies.
BeOne Medicines Ltd. is a global biotechnology company that specializes in oncology medicines, particularly for blood cancers and solid tumors.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
